Action 6996 ANTENGENE CORPORATION LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Antengene Corporation Limited

Actions

6996

KYG039571008

Marché Fermé - Hong Kong S.E.
Autres places de cotation
 10:08:09 16/07/2024 		Varia. 5j. Varia. 1 janv.
0,74 HKD +2,78 % Graphique intraday de Antengene Corporation Limited +8,82 % -63,00 %
08/07 Le médicament anticancéreux d'Antengene approuvé pour une nouvelle indication en Chine MT
05/07 Antengene Corporation Limited annonce que l'Administration nationale chinoise des produits médicaux (NMPA) approuve une nouvelle indication dans le DLBCL en Chine, offrant ainsi une nouvelle option thérapeutique aux patients du pays CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Antengene Corporation - XPOVIO Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country
AQ
XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country
PR
Antengene Announces XPOVIO National Health Insurance Service Approval for Reimbursement in South Korea
AQ
Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea
PR
Antengene Announces One Oral and Three Poster Presentations at ASCO 2024
AQ
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress across First-in-Class, Best-in-Class Pipeline
AQ
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms
AQ
Antengene Announces Inclusion of XPOVIO in 2023 China's National Reimbursement Drug List
AQ
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List
PR
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States
AQ
Antengene Announces XPOVIO Regulatory Approval in Macau for the Treatment of Relapsed and or Refractory Multiple Myeloma
AQ
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
PR
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day
AQ
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day
PR
Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs
PR
Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting
PR
Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting
PR
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031
AQ
Antengene Voluntarily Lowers the Price of XPOVIO in China to Allow More Patients with Multiple Myeloma to Benefit from the Drug
AQ
Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 6996
  4. Actualités Antengene Corporation Limited
  5. Communiqués